Exane Derivatives Vertex Pharmaceuticals Inc Transaction History

Exane Derivatives

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$234.96 - $292.55 $730,490 - $909,537	-3,109 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$221.42 - $260.97 $688,394 - $811,355	3,109 New	3,109 $811,000
Q4 2021 Jan 28, 2022	SELL	$177.01 - $223.45 $181,258 - $228,812	-1,024 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$181.39 - $202.99 $12,697 - $14,209	70 Added 7.34%	1,024 $185,000
Q2 2021 Jul 28, 2021	BUY	$187.49 - $221.1 $41,810 - $49,305	223 Added 30.51%	954 $192,000
Q1 2021 Apr 30, 2021	BUY	$207.02 - $241.31 $151,331 - $176,397	731 New	731 $157,000
Q4 2020 Jan 27, 2021	SELL	$207.01 - $276.09 $396,631 - $528,988	-1,916 Closed	0 $0
Q3 2020 Oct 08, 2020	BUY	$255.65 - $303.1 $489,825 - $580,739	1,916 New	1,916 $521,000
Q3 2020 Oct 06, 2020	SELL	$255.65 - $303.1 $413,130 - $489,809	-1,616 Closed	0 $0
Q2 2020 Jul 10, 2020	SELL	$225.48 - $295.8 $185,119 - $242,851	-821 Reduced 33.69%	1,616 $469,000
Q1 2020 Apr 17, 2020	BUY	$199.77 - $247.81 $476,850 - $591,522	2,387 Added 4774.0%	2,437 $579,000
Q4 2019 Jan 22, 2020	SELL	$166.71 - $223.91 $177,712 - $238,688	-1,066 Reduced 95.52%	50 $10,000
Q2 2019 Jul 12, 2019	BUY	$164.61 - $190.37 $175,968 - $203,505	1,069 Added 2274.47%	1,116 $0
Q1 2019 Apr 24, 2019	SELL	$163.73 - $194.7 $123,452 - $146,803	-754 Reduced 94.13%	47 $0
Q3 2018 Oct 24, 2018	BUY	$167.73 - $192.74 $15,431 - $17,732	92 Added 12.98%	801 $0
Q1 2018 Apr 30, 2018	BUY	$151.6 - $177.13 $107,332 - $125,408	708 Added 70800.0%	709 $0
Q3 2017 Oct 18, 2017	BUY	$148.13 - $162.24 $148 - $162	1	1 $0

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $125B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.